WST Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 22:59):

Stats
Šios dienos apimtis	359 575
Vidutinė apimtis	544 086
Rinkos kapitalizacija	26.84B
EPS	$1.830 ( 2024-04-25 )
Kita pelno data	( $1.820 ) 2024-07-25
Last Dividend	$0.200 ( 2023-11-07 )
Next Dividend	$0 ( N/A )
P/E	48.48
ATR14	$0.239 (0.06%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-23	Pucci Paolo	Buy	564	Common Stock
2024-04-23	Michels Douglas A	Buy	564	Common Stock
2024-04-23	Lai Goldman Myla	Buy	564	Common Stock
2024-04-23	Lockhart Stephen H	Buy	564	Common Stock
2024-04-23	Keller Deborah L	Buy	564	Common Stock

INSIDER POWER
-9.46
Last 100 transactions
Buy: 235 088 \| Sell: 288 836

Tūris Koreliacija

Ilgas: 0.15 (neutral)

Trumpas: -0.59 (weak negative)

Signal:(72.923) Neutral

West Pharmaceutical Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

West Pharmaceutical Koreliacija - Valiuta/Žaliavos

0.31
( neutral )

0.13
( neutral )

-0.42
( neutral )

0.06
( neutral )

-0.16
( neutral )

0.36
( neutral )

West Pharmaceutical Finansinės ataskaitos

Annual	2023
Pajamos:	$2.95B
Bruto pelnas:	$1.13B (38.28 %)
EPS:	$7.99

FY	2023
Pajamos:	$2.95B
Bruto pelnas:	$1.13B (38.28 %)
EPS:	$7.99

FY	2022
Pajamos:	$2.89B
Bruto pelnas:	$1.14B (39.36 %)
EPS:	$7.88

FY	2021
Pajamos:	$2.83B
Bruto pelnas:	$1.18B (41.52 %)
EPS:	$8.96

Financial Reports:

No articles found.

West Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.180 (N/A)	$0.190 (N/A)	$0.190 (N/A)	$0.190 (N/A)	$0.190 (N/A)	$0.200 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

West Pharmaceutical Dividend Information - Dividend King

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.82 - Stable (36.49%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0163	1987-01-26
Last Dividend	$0.200	2023-11-07
Next Dividend	$0	N/A
Payout Date	2023-11-15
Next Payout Date	N/A
# dividends	148	--
Total Paid Out	$11.05	--
Avg. Dividend % Per Year	0.18%	--
Score	5.52	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.82
Div. Directional Score	9.81	--

Next Divdend (Est)
(2024-07-01)

$0.202 Estimate 40.00 %

Dividend Stability

0.80 Very Good

Dividend Score

5.52

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1987	$0.0676	1.90%
1988	$0.0726	1.70%
1989	$0.0776	1.97%
1990	$0.100	2.12%
1991	$0.100	3.30%
1992	$0.100	2.19%
1993	$0.103	1.82%
1994	$0.113	1.84%
1995	$0.123	1.79%
1996	$0.133	2.23%
1997	$0.143	2.04%
1998	$0.153	2.06%
1999	$0.163	1.86%
2000	$0.173	2.28%
2001	$0.183	2.98%
2002	$0.190	2.85%
2003	$0.203	3.29%
2004	$0.213	2.49%
2005	$0.225	1.78%
2006	$0.245	1.89%
2007	$0.265	1.04%
2008	$0.285	1.41%
2009	$0.305	1.60%
2010	$0.325	1.65%
2011	$0.345	1.65%
2012	$0.365	1.91%
2013	$0.385	1.39%
2014	$0.410	0.84%
2015	$0.450	0.86%
2016	$0.490	0.85%
2017	$0.530	0.63%
2018	$0.570	0.57%
2019	$0.610	0.63%
2020	$0.650	0.43%
2021	$0.690	0.24%
2022	$0.730	0.16%
2023	$0.770	0.33%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
ZTR	Dividend Royal	2024-02-09	Monthly	37	8.35%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.194	1.500	6.12	9.17	[0 - 0.5]
returnOnAssetsTTM	0.158	1.200	4.74	5.69	[0 - 0.3]
returnOnEquityTTM	0.204	1.500	8.85	10.00	[0.1 - 1]
payoutRatioTTM	0.101	-1.000	8.99	-8.99	[0 - 1]
currentRatioTTM	2.61	0.800	1.946	1.556	[1 - 3]
quickRatioTTM	1.736	0.800	4.49	3.59	[0.8 - 2.5]
cashRatioTTM	0.928	1.500	5.95	8.93	[0.2 - 2]
debtRatioTTM	0.0851	-1.500	8.58	-10.00	[0 - 0.6]
interestCoverageTTM	76.61	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	10.29	2.00	6.57	10.00	[0 - 30]
freeCashFlowPerShareTTM	5.25	2.00	7.37	10.00	[0 - 20]
debtEquityRatioTTM	0.114	-1.500	9.54	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.372	1.000	7.14	7.14	[0.2 - 0.8]
operatingProfitMarginTTM	0.220	1.000	7.61	7.61	[0.1 - 0.6]
cashFlowToDebtRatioTTM	2.47	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.813	0.800	7.91	6.33	[0.5 - 2]
Total Score				12.80

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	46.97	1.000	5.36	0	[1 - 100]
returnOnEquityTTM	0.204	2.50	9.26	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	5.25	2.00	8.25	10.00	[0 - 30]
dividendYielPercentageTTM	0.217	1.500	4.57	0	[0 - 0.4]
operatingCashFlowPerShareTTM	10.29	2.00	6.57	10.00	[0 - 30]
payoutRatioTTM	0.101	1.500	8.99	-8.99	[0 - 1]
pegRatioTTM	7.52	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.258	1.000	6.04	0	[0.1 - 0.5]
Total Score				6.82

West Pharmaceutical

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.